Efficacy and safety results of TQB2930, a HER2-targeted bispecific antibody combined with chemotherapy in patients with HER2-positive breast cancer (BC) previously treated with ≥2 line treatments: Results from a phase 1b/2 study
机构：[1]Breast Department, Harbin Medical University Cancer Hospital, Harbin, China[2]Harbin Medical University Cancer Hospital, Harbin, China[3]Changde Hospital, Xiangya School of Medicine, Central South University, Changde, China[4]Guangxi Medical University Cancer Hospital, Nanning, China[5]Chongqing University Cancer Hospital, Chonqqing, China[6]Liaoning Cancer Hospital, Shenyang, China[7]The Cancer Center of the Fifth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China[8]Special Medical Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China[9]The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China[10]Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China[11]Anyang Tumor Hospital, Anyang, China[12]Breast Disease Control Center, Maternal and Child Health Care Hospital of Guangdong Province, Guangzhou, China[13]Xiangya Third Hospital of Central South University, Changsha, China[14]The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China[15]Department of Chemotherapy Oncology, Anhui Provincial Hospital, Hefei, China[16]Tangshan People’s Hospital, Tangshan, China[17]The Affiliated Hospital of Hebei University, Shi Jia Zhuang, China河北大学附属医院
第一作者机构：[1]Breast Department, Harbin Medical University Cancer Hospital, Harbin, China
推荐引用方式(GB/T 7714)：
Qingyuan Zhang,Wenhui Zhao,Jingxuan Wang,et al.Efficacy and safety results of TQB2930, a HER2-targeted bispecific antibody combined with chemotherapy in patients with HER2-positive breast cancer (BC) previously treated with ≥2 line treatments: Results from a phase 1b/2 study[J].JOURNAL OF CLINICAL ONCOLOGY.2025,43(16_SUPPL):1033-1033.doi:10.1200/JCO.2025.43.16_suppl.1033.
APA：
Qingyuan Zhang,Wenhui Zhao,Jingxuan Wang,Tao Wu,Weimin Xie...&Hua Yang.(2025).Efficacy and safety results of TQB2930, a HER2-targeted bispecific antibody combined with chemotherapy in patients with HER2-positive breast cancer (BC) previously treated with ≥2 line treatments: Results from a phase 1b/2 study.JOURNAL OF CLINICAL ONCOLOGY,43,(16_SUPPL)
MLA：
Qingyuan Zhang,et al."Efficacy and safety results of TQB2930, a HER2-targeted bispecific antibody combined with chemotherapy in patients with HER2-positive breast cancer (BC) previously treated with ≥2 line treatments: Results from a phase 1b/2 study".JOURNAL OF CLINICAL ONCOLOGY 43..16_SUPPL(2025):1033-1033
医学